Australian Cancer Technology
Patient enrollment almost complete in study of vaccine for prostate cancer
Published in Medicine and Law Weekly, April 8th, 2005
The multicenter open label phase IIb study is being conducted by Cancer Trials Australia, a consortium of four Melbourne Hospitals and three Research Institutes. Of these, the three consortium members participating in the study include Melbourne's Austin Health, Royal Melbourne Hospital and the Peter MacCallum Cancer Center.
To date, 36 of the 40 anticipated participants in the study have been enrolled and dosed. The study is designed to confirm the safety...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- AIDS Healthcare Foundation
Legal order allows challenge to AIDS drug pricing in South African to go forward - Albert Einstein College of Medicine
Anti-CXCR4 antibodies differ significantly in ability to inhibit HIV entry - American College of Physician Executives
Survey showing unethical business practices in U.S. healthcare alarms physicians - Applied NeuroSolutions
Patent issued for Alzheimer blood test technology - AstraZeneca
EPO rules Symbicort combination patent still valid - Awards
Houston, Texas, attorneys named fellows of American Health Lawyers Association - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
